Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
Beute
Jan
J
D002316:Cardiotonic Agents / Q000627:therapeutic use*; D017335:Enoximone / Q000627:therapeutic use*; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications*; D011724:Pyridazines / Q000627:therapeutic use*; D012770:Shock, Cardiogenic / Q000188:drug therapy* / Q000209:etiology*; D000077464:Simendan
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan; D017335:Enoximone